Validation of [18F]FES for Imaging of Brain Estrogen Receptors

Status Terminated

Clinical Trial Summary

Validation of [18F]-FES for imaging of estrogen receptors in the brain The primary objective of the study is to determine if [18F]-FES Positron Emission Tomography (PET) can be used to quantify the estrogen receptor expression in the human brain.

Clinical Trial Description

Estrogens are the primary female sex hormones that play a major role in the development and maintenance of secondary sexual functions. In addition, estrogens play an important role in cardiovascular, musculoskeletal, immunological, bone development and central nervous system processes. Actions of estrogens are mediated by a group of specialized receptors, known as estrogen receptors. Estrogens were found to be neuroprotective and may thus protect against development of neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and multiple sclerosis. In addition, estrogens may also play an important role in psychiatric disorders, like depression. To improve our understanding of the action of estrogens in the brain, it is important to study the expression of estrogen receptors in the brain. Positron emission tomography (PET) is the most suitable technique for non-invasive imaging of brain receptors. [18F]FES is a PET tracer that is regularly used in the UMCG to image the estrogen receptor expression in breast cancer patients, but has never been used for quantitative imaging of brain estrogen receptors. Quantification of the expression of brain receptors by PET usually requires arterial blood sampling to obtain the plasma input function of the tracer. Arterial blood sampling causes discomfort to the patient and therefore can be an obstacle especially in longitudinal studies. The aim of this study is therefore to investigate whether [18F]FES PET imaging for quantification of estrogen receptors in the human brain is feasible without arterial blood sampling, using a reference tissue model (SRTM) or an image derived input function (IDIF), so the discomfort associated with arterial blood sampling can be avoided. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01842217
Study type	Interventional
Source	University Medical Center Groningen
Contact
Status	Terminated
Phase	N/A
Start date	November 2013
Completion date	January 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02235051` - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors	N/A
Completed	`NCT01635413` - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)	N/A
Completed	`NCT00701337` - Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route	Phase 4
Recruiting	`NCT04705623` - Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women	N/A
Withdrawn	`NCT03238703` - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer	Phase 4
Completed	`NCT03756272` - Stellate Ganglion Block to Reduce Hot Flushes	N/A
Recruiting	`NCT03953157` - Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors	N/A
Completed	`NCT00338728` - Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT01482702` - Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors	N/A
Not yet recruiting	`NCT05009238` - Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women	N/A
Completed	`NCT01172574` - Motor Control Exercise in Osteoporotic Women	N/A
Completed	`NCT00530582` - Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women	Phase 4
Completed	`NCT01825785` - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)	Phase 1
Completed	`NCT04364061` - Post Exercise Substrate Oxidation, Appetite and Energy Intakes in Overweight/Obese Postmenopausal Women (EScAPE)	N/A
Completed	`NCT03180294` - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer	Phase 2
Completed	`NCT01753908` - Broccoli Sprout Extract in Treating Patients With Breast Cancer	Early Phase 1
Not yet recruiting	`NCT06377631` - Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity	N/A
Recruiting	`NCT06228768` - Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer	N/A
Terminated	`NCT01294397` - Effects of Denosumab on the Pharmacokinetics of Etanercept	Phase 1
Completed	`NCT00603967` - Effect of Aromatase Inhibitors on Bones and Genes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.